Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study

被引:15
|
作者
Chu, Shou-Sheng [1 ]
Kuo, Yu-Hsuan [2 ,3 ]
Liu, Wen-Shan [4 ,5 ,6 ]
Wang, Shih-Chang [7 ]
Ho, Chung-Han [8 ,9 ]
Chen, Yi-Chen [8 ]
Yang, Ching-Chieh [1 ,10 ]
Wu, Hung-Chang [2 ,10 ]
机构
[1] Chi Mei Med Ctr, Dept Radiat Oncol, 901 Zhonghua Rd, Tainan 701, Taiwan
[2] Chi Mei Med Ctr, Dept Hematol & Oncol, 901 Zhonghua Rd, Tainan 701, Taiwan
[3] Chia Nan Univ Pharm & Sci, Dept Cosmet Sci, Tainan, Taiwan
[4] Kaohsiung Vet Gen Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan
[5] Meiho Univ, Dept Nursing, Pingtung, Taiwan
[6] Natl Def Med Ctr, Sch Med, Taipei, Taiwan
[7] Antai Med Care Corp Antai Tian Sheng Mem Hosp, Dept Radiat Oncol, Pingtung, Taiwan
[8] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan
[9] Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm, Tainan, Taiwan
[10] Chia Nan Univ Pharm & Sci, Dept Pharm, Tainan, Taiwan
关键词
RADIATION-THERAPY; OUTCOMES; CIRRHOSIS; PATTERNS; PHASE-2;
D O I
10.1038/s41598-021-81176-w
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) patients. This study aims to determine whether combining radiotherapy with sorafenib administration increases its efficacy. The study cohort included 4763 patients with diagnosed advanced HCC who received sorafenib between January 2012 and December 2015, as reported in medical records in the Taiwan Cancer Registry database. The effect of sorafenib with or without radiotherapy on survival was calculated using the Kaplan-Meier method and compared using the log-rank test. A Cox proportional hazards model was used for multivariate analysis. Patients receiving sorafenib plus radiotherapy had greater 1-year survival than did those receiving sorafenib alone (P<0.001). Uni- and multivariate analyses also showed that radiotherapy increased survival after adjusting for confounders (adjusted HR 0.57; 95% CI 0.51-0.63). Further stratified analysis according to the timing of radiotherapy relative to sorafenib treatment revealed that patients who underwent radiotherapy after sorafenib had greater 1-year survival than did those undergoing radiotherapy within sorafenib use or sorafenib alone (adjusted HR 0.39; 95% CI 0.27-0.54). Combined treatment with sorafenib and radiotherapy results in greater HCC patient survival and should be considered an option for treating this challenging disease.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
    Shou-Sheng Chu
    Yu-Hsuan Kuo
    Wen-Shan Liu
    Shih-Chang Wang
    Chung-Han Ho
    Yi-Chen Chen
    Ching-Chieh Yang
    Hung-Chang Wu
    [J]. Scientific Reports, 11
  • [2] Advanced hepatocellular carcinoma treated by a combination of sorafenib and radiotherapy
    Yang, Bi-Ling
    Yeh, Chun
    Hsu, Chung-Te
    Chang, Tien-Yu
    Wang, Chung-Yih
    [J]. ADVANCES IN DIGESTIVE MEDICINE, 2014, 1 (01) : 25 - 29
  • [3] Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with Sorafenib
    Antonelli, G.
    Gigante, E.
    Iavarone, M.
    Begini, P.
    Biondetti, P.
    Pellicelli, A. M.
    Sangiovanni, A.
    Lampertico, P.
    Marignani, M.
    [J]. JOURNAL OF HEPATOLOGY, 2018, 68 : S207 - S208
  • [4] Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
    Otsuka, Taiga
    Eguchi, Yuichiro
    Kawazoe, Seiji
    Yanagita, Kimihiko
    Ario, Keisuke
    Kitahara, Kenji
    Kawasoe, Hiroaki
    Kato, Hiroyuki
    Mizuta, Toshihiko
    [J]. HEPATOLOGY RESEARCH, 2012, 42 (09) : 879 - 886
  • [5] Analysis of postprogression survival of patients with advanced hepatocellular carcinoma treated with sorafenib
    Wada, Y.
    Takami, Y.
    Matsushima, H.
    Ryu, T.
    Mikagi, K.
    Saitsu, H.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S630 - S631
  • [6] Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
    Antonelli, G.
    Gigante, E.
    Iavarone, M.
    Begini, P.
    Sangiovanni, A.
    Iannicelli, E.
    Biondetti, P.
    Pellicelli, A. M.
    Miglioresi, L.
    Marchetti, P.
    Lampertico, P.
    Marignani, M.
    [J]. DIGESTIVE AND LIVER DISEASE, 2018, 50 (01) : 14 - 14
  • [7] Impact of Radiotherapy On Survival In Patients With Unresectable Hepatocellular Carcinoma Receiving Sorafenib: A Nation-Wide Cancer Registry-Based Study
    Chu, S. S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E630 - E631
  • [8] Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma
    Peixoto, Renata D'Alpino
    Renouf, Daniel J.
    Gill, Sharlene
    Cheung, Winson Y.
    Lim, Howard J.
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 5 (04) : 259 - 264
  • [9] Impact of statin on the survival of patients with advanced hepatocellular carcinoma treated with sorafenib or lenvatinib
    Cho, Hyo Jung
    Han, Ji Eun
    Cheong, Jae Youn
    Kim, Soon Sun
    [J]. JOURNAL OF HEPATOLOGY, 2023, 78 : S572 - S572
  • [10] IMPACT OF SARCOPENIA ON SURVIVAL OF PATIENTS AFFECTED BY ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB
    Reggidori, N.
    Lani, L.
    Renzulli, M.
    Gramenzi, A.
    Iannone, G.
    Granito, A.
    Piscaglia, F.
    Golfieri, R.
    Trevisani, F.
    Biselli, M.
    [J]. DIGESTIVE AND LIVER DISEASE, 2022, 54 : S151 - S151